We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more
Ask ADVFN Intelligence (AI)
BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the second quarter ended June 30, 2024, and provided an...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and...
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.588235294118 | 1.7 | 1.77 | 1.67 | 43287 | 1.71652355 | CS |
| 4 | 0.04 | 2.39520958084 | 1.67 | 1.77 | 1.66 | 38604 | 1.70345853 | CS |
| 12 | -0.02 | -1.15606936416 | 1.73 | 1.87 | 1.6 | 59115 | 1.70150585 | CS |
| 26 | 0.37 | 27.6119402985 | 1.34 | 1.88 | 1.22 | 194235 | 1.59707327 | CS |
| 52 | -2.47 | -59.0909090909 | 4.18 | 4.625 | 1.02 | 254801 | 1.57731263 | CS |
| 156 | -10.29 | -85.75 | 12 | 17.5 | 1.02 | 171949 | 3.98990776 | CS |
| 260 | -20.69 | -92.3660714286 | 22.4 | 37.61 | 1.02 | 169790 | 5.97874976 | CS |
Monksdream
3 months ago
Monksdream
3 months ago
Monksdream
3 months ago
glenn1919
5 months ago
Monksdream
7 months ago
Monksdream
8 months ago
herbied47
11 months ago
herbied47
11 months ago
Tacostocks
11 months ago
Money hunt
11 months ago
Tacostocks
11 months ago
AJ Freely
1 year ago
Tartiaboy
2 years ago
TrendTrade2016
2 years ago
TrendTrade2016
2 years ago
crudeoil24
4 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
